| Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) |
Ongoing |
Heparin - Enoxaparin - Tinzaparin - Fondaparinux |
3 |
1.2 |
King Khalid University Hospital (Riyadh) |
| "Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic ( RAPID COVID COAG) " |
Completed |
TINZAPARIN SODIUM |
3 |
RC20/403 |
King Abdulaziz Medical City NG (Riyadh) |
| Circulating Endotoxin as a Contributing Inflammatory Mediator in Osteoporosis Risk and its Association with Vitamin D Deficiency |
Ongoing |
Vitamin D3 VS. Alendronate |
3 |
11-MED-2113-02 or (G1109-665) |
KFMC |
| Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial |
Ongoing |
VITAMIN D3 (CHOLECALCIFEROL) |
3 |
IRB#16-252, V2 |
KAMC |
| Bi-weekly Cetuximab and XELIRI(Capecitabine and Irinotecan) as first line therapy in K/N-RAS wild type advanced colorectal cancer: Phase I-II CETUXIRI study |
Completed |
Cetuximab |
1/2 |
1 , 29/07/2015 |
KFSH&RC-R |
| Autologous Bone marrow derived osteoblasts in the Management of Avascular Necrosis of the Head of Femur: A Phase II |
Rejected |
Osteoblasts Stem cells |
2 |
2018-01-315 |
King Fahad University Hospital (Al-Khobar) |
| Autologous Bone Marrow Derived Chondrocytes in the Management of Osteoarthritis of Knee: A Phase II Clinical Trial. |
Rejected |
Chondrocytes Stemcells |
2 |
2018-01-314 |
King Fahad University Hospital (Al-Khobar) |
| Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT) |
Completed |
Aspirin |
3 |
ICR-02/ASCOLT |
KFMC |
| An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies" |
Completed |
TKI258 / Sorafenib |
3 |
CTKI258A2302 |
KFSH & RC-R |
| An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE). |
Rejected |
RAD001 (Everolimus) |
2 |
CRAD001LIC01 |
KFSH & RC-R |
